IOVA

Iovance Biotherapeutics Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↑ 5/10
  • Momentum↑ 6/10
Iovance Biotherapeutics sales and earnings growth
IOVA Growth
Neutral
  • Revenue Y/Y↑ 175.62%
  • EPS Y/Y↑ 20.13%
  • FCF Y/Y↑ 5.95%
Iovance Biotherapeutics gross and profit margin trends
IOVA Profitability
Neutral
  • Gross margin ↑ 24.00%
  • EPS margin↓ -158.80%
  • ROIC↓ -96.30%
Iovance Biotherapeutics net debt vs free cash flow
IOVA Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Iovance Biotherapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗